TENECTEPLASE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Injection 25mg (5,000 units) (Restricted: hospital use only)

Dosage:

First line for acute ischaemic stroke - As per SMC 2697: in adults for the thrombolytic treatment of acute ischaemic stroke within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.

Guideline: ED Stroke thrombolysis pathway - Raigmore (Guidelines) | Right Decisions (scot.nhs.uk)

Important: Formulation and dosage details

Formulation:

Injection 50mg (10,000 units) (Restricted: hospital use only)

Dosage:

Acute myocardial infarction

Guideline: Acute coronary syndrome

ALTEPLASE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Injection 10mg (5·8 million units/vial), 20mg (11·6 million units/vial), 50mg (29 million units/vial) (hospital use only)

Dosage:

Second line after tenecteplase: Hyper-acute stroke presenting within 4·5 hours of onset of symptoms: refer to ED Stroke thrombolysis pathway - Raigmore (Guidelines)  
Pulmonary embolism and empyema [off-label]: See Allergic emergencies.

UROKINASE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Injection 10,000 units, 25,000 units, 100,000 units (hospital use only)

Editorial Information

Document Id: F059